ethyl (2S)-3-[4-[(E)-3-[3,5-bis(trifluoromethyl)phenyl]prop-2-enoxy]phenyl]-2-ethoxypropanoate | 352287-82-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl (2S)-3-[4-[(E)-3-[3,5-bis(trifluoromethyl)phenyl]prop-2-enoxy]phenyl]-2-ethoxypropanoate
• CAS: 352287-82-2
• 化学式: C₂₄H₂₄F₆O₄
• 分子量: 490.443
• InChiKey: FNMRRSVHHOYCQT-LYSGITKLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  ethyl (2S)-3-[4-[(E)-3-[3,5-bis(trifluoromethyl)phenyl]prop-2-enoxy]phenyl]-2-ethoxypropanoate 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 (S)-3-(4-(3,5-bis(trifluoromethyl)cinnamyloxy)phenyl)-2-ethoxypropanoic acid
  参考文献：
  名称：

  Design of potent PPARα agonists

  摘要：

  Computational analysis of the ligand binding pocket of the three PPAR receptor subtypes was utilized in the design of potent PPAR alpha agonists. Optimum PPAR alpha potency and selectivity were obtained with substituents having van der Waals volume around 260. Compound 6 had a PPAR alpha potency of 0.002 mu M and a selectivity ratio to PPAR gamma and PPAR delta of 410 and 2000, respectively. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.015
• 作为产物：
  描述：

  3,5-双三氟甲基苯甲醛 在 三丁基膦 、 sodium hydride 、 二异丁基氢化铝 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 四氢呋喃 、 甲苯 、 苯 为溶剂， 生成 ethyl (2S)-3-[4-[(E)-3-[3,5-bis(trifluoromethyl)phenyl]prop-2-enoxy]phenyl]-2-ethoxypropanoate
  参考文献：
  名称：

  Design of potent PPARα agonists

  摘要：

  Computational analysis of the ligand binding pocket of the three PPAR receptor subtypes was utilized in the design of potent PPAR alpha agonists. Optimum PPAR alpha potency and selectivity were obtained with substituents having van der Waals volume around 260. Compound 6 had a PPAR alpha potency of 0.002 mu M and a selectivity ratio to PPAR gamma and PPAR delta of 410 and 2000, respectively. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.015

文献信息

• Compounds, their preparation and use
  申请人：——

  公开号：US20030195200A1

  公开（公告）日：2003-10-16

  The present invention relates to compounds of the general formula (I) 1 The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及一般式(I)的化合物，这些化合物在治疗和/或预防由核受体介导的疾病方面具有用处，特别是过氧化物酶体增殖物激活受体（PPAR）。
• US6555577B1
  申请人：——

  公开号：US6555577B1

  公开（公告）日：2003-04-29
• US6867218B2
  申请人：——

  公开号：US6867218B2

  公开（公告）日：2005-03-15
• Design of potent PPARα agonists
  作者：Per Sauerberg、John P. Mogensen、Lone Jeppesen、Paul S. Bury、Jan Fleckner、Grith S. Olsen、Claus B. Jeppesen、Erik M. Wulff、Pavel Pihera、Miroslav Havranek、Zdenek Polivka、Ingrid Pettersson

  DOI：10.1016/j.bmcl.2007.03.015

  日期：2007.6

  Computational analysis of the ligand binding pocket of the three PPAR receptor subtypes was utilized in the design of potent PPAR alpha agonists. Optimum PPAR alpha potency and selectivity were obtained with substituents having van der Waals volume around 260. Compound 6 had a PPAR alpha potency of 0.002 mu M and a selectivity ratio to PPAR gamma and PPAR delta of 410 and 2000, respectively. (C) 2007 Elsevier Ltd. All rights reserved.